Battling global anti-microbial resistance – ILSE and CARB-X
The Institute for Life Science Entrepreneurship at Kean University (ILSE) is joining a network of committed scientists and experts in the international race to develop new antibiotics, vaccines, diagnostics and other products to fight drug-resistant superbugs. ILSE joins a global network of accelerators across the globe and will provide scientific, business and operations support to projects in the CARB-X portfolio. ILSE will also develop meaningful informational and networking programs on topics central to advancing the mission of CARB-X and its companies.
ILSE and CARB-X (Combating Antibiotic Resistant Bacterial Biopharmaceutical Accelerator), have reached a 3-year agreement under which ILSE will serve as an accelerator in the CARB-X Global Accelerator Network and provide knowhow, diagnostics expertise, business strategy and other support to CARB-X’s growing portfolio of innovative antibacterial development projects.
CARB-X is a non-profit global partnership funded by the US government’s Biomedical and Advanced Research Authority (BARDA), the Wellcome Trust, the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), and the Bill & Melinda Gates Foundation, with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). CARB-X is based at the Boston University School of Law.
Learn more about CARB-X and the ILSE Announcement here.
About the CARB-X Global Accelerator Network
The CARB-X Global Accelerator Network is a network of organizations that provide business, scientific and technical expertise and services to CARB-X-funded companies to support their antibacterial research projects. The Network also plays a key role in addressing common challenges facing the antibacterial product development community. Members of the CARB-X Accelerator Network include BaselArea.swiss, Basel, Switzerland; the BioInnovation Institute (BII), Copenhagen, Denmark; the California Life Sciences Institute (CLSI), South San Francisco, CA, USA; the Centre for Cellular and Molecular Platforms (C-CAMP), Bangalore, India; the Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland; the German Center for Infection Research (DZIF), Braunschweig, Germany; the Institute for Life Science Entrepreneurship (ILSE), Union, NJ, USA; Massachusetts Biotechnology Council (MassBio), Cambridge, MA, USA; RTI International, Research Triangle Park, NC, USA; and Wellcome Trust, London, UK, which is also a CARB-X funding partner.